Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Vaxart Inc

Healthcare US VXRT

0.62USD
0.02(3.32%)

Last update at 2026-06-04T17:40:00Z

Day Range

0.590.62
LowHigh

52 Week Range

0.531.54
LowHigh

Fundamentals

  • Previous Close 0.60
  • Market Cap146.63M
  • Volume74614
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-74.72300M
  • Revenue TTM7.38M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM -80.94700M
  • Diluted EPS TTM-0.5

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -107.69100M -70.36300M -31.98200M -8.31500M -17.89800M
Minority interest - - - - -
Net income -107.75800M -70.47000M -32.22000M -8.80500M -18.00700M
Selling general administrative 29.39M 21.89M 15.20M 6.19M 6.68M
Selling and marketing expenses - - - - -
Gross profit 0.11M 0.89M 4.05M 9.86M 4.16M
Reconciled depreciation 5.80M 4.21M 2.71M 3.60M 3.20M
Ebit -114.58700M -72.75200M -30.17000M -19.38100M -27.80100M
Ebitda -106.07900M -66.74200M -31.86800M -15.78500M -24.59800M
Depreciation and amortization 8.51M 6.01M -1.69800M 3.60M 3.20M
Non operating income net other -0.00600M -0.00100M -0.01300M -2.20400M 4.68M
Operating income -114.58700M -72.75200M -30.17000M -15.78500M -21.75600M
Other operating expenses 110.44M 70.64M 35.06M 20.73M 23.96M
Interest expense 1.30M 1.48M 1.87M 2.39M 2.68M
Tax provision 0.07M 0.11M 0.24M 0.49M 0.11M
Interest income 1.25M 0.08M 0.07M 0.15M 0.06M
Net interest income -0.05800M -1.39900M -1.79900M -2.23900M -2.62200M
Extraordinary items - - - - -
Non recurring 4.25M 3.00M - 4.92M -
Other items - - - - -
Income tax expense 0.07M 0.11M 0.24M 0.49M 0.11M
Total revenue 0.11M 0.89M 4.05M 9.86M 4.16M
Total operating expenses 110.44M 70.64M 35.06M 20.73M 23.96M
Cost of revenue - - - 14.54M 25.91M
Total other income expense net 6.90M 2.39M -1.81200M 7.47M 1.90M
Discontinued operations - - - - -
Net income from continuing ops -107.75800M -70.47000M -32.22000M -18.64500M -18.00700M
Net income applicable to common shares -107.75800M -70.47000M -32.22000M -18.64500M -18.34600M
Preferred stock and other adjustments - - - - 0.34M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 91.83M 153.85M 221.17M 152.58M 37.03M
Intangible assets 4.29M 5.02M 10.62M 15.36M 17.09M
Earning assets - - - - -
Other current assets 2.81M 3.71M 2.61M 1.33M 0.45M
Total liab 34.02M 43.25M 33.64M 29.18M 24.08M
Total stockholder equity 57.80M 110.60M 187.53M 123.40M 12.95M
Deferred long term liab - - - - -
Other current liab 5.63M 6.09M 1.57M 2.78M 2.92M
Common stock 0.01M 0.01M 0.01M 0.01M 4.83M
Capital stock 0.01M 0.01M 0.01M 0.01M 4.83M
Retained earnings -409.57400M -327.10900M -219.35100M -148.88100M -116.66100M
Other liab - 5.85M 10.86M 14.93M 13.43M
Good will 4.51M 4.51M 4.51M - -
Other assets - 3.57M 0.89M 0.37M 0.14M
Cash 34.76M 46.01M 143.75M 126.87M 13.53M
Cash and equivalents - - - - -
Total current liabilities 13.72M 15.83M 9.11M 7.04M 5.43M
Current deferred revenue - 2.00M 2.65M 0.08M 0.83M
Net debt -8.24100M -22.08000M -130.73700M -119.66200M -11.21300M
Short term debt 6.51M 2.23M 1.01M 2.05M 0.84M
Short long term debt - - - - -
Short long term debt total 26.51M 23.93M 13.01M 7.21M 2.31M
Other stockholder equity 467.37M 437.99M 406.94M 272.27M 124.79M
Property plant equipment - 15.59M 6.60M 1.48M 0.21M
Total current assets 45.54M 95.74M 147.31M 128.90M 17.74M
Long term investments - 0.00000M 16.21M - -
Net tangible assets - 110.60M 187.53M 123.40M 12.95M
Short term investments 4.96M 49.70M 38.95M - -
Net receivables 3.01M 0.02M 0.07M 0.33M 3.62M
Long term debt - - - - -
Inventory 0.00000M -3.71400M 0.89M 0.37M 0.14M
Accounts payable 1.58M 5.51M 3.87M 2.13M 0.85M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.00100M -0.29900M -0.07400M - -0.45900M
Additional paid in capital - - - - -
Common stock total equity - 0.01M 0.01M 0.01M 4.83M
Preferred stock total equity - - - - -
Retained earnings total equity - -327.10900M -219.35100M -148.88100M -116.66100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.93M 7.28M 0.89M 0.37M 0.14M
Deferred long term asset charges - - - - -
Non current assets total 46.29M 58.11M 73.85M 23.68M 19.29M
Capital lease obligations 20.09M 21.70M 13.01M 7.21M 2.31M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -10.81400M -39.11100M -1.22000M -0.85000M 1.42M
Change to liabilities -4.96600M -0.58300M 0.63M 2.25M -10.17700M
Total cashflows from investing activities -20.41500M -49.09700M -1.22000M -0.85000M 26.21M
Net borrowings - - - 3.80M -1.74200M
Total cash from financing activities 17.46M 125.80M 138.31M 15.96M -1.72900M
Change to operating activities -7.10600M -4.00900M -1.68700M 3.17M -7.26600M
Net income -107.75800M -70.47000M -32.22000M -18.64500M -18.00700M
Change in cash -97.73200M 16.88M 113.34M 2.02M 9.94M
Begin period cash flow 143.75M 126.87M 13.53M 11.51M 1.57M
End period cash flow 46.01M 143.75M 126.87M 13.53M 11.51M
Total cash from operating activities -94.77900M -59.83200M -23.75000M -13.09000M -14.54800M
Issuance of capital stock 17.24M 122.21M 111.11M 18.35M -
Depreciation 5.80M 4.21M 2.71M 3.60M 3.20M
Other cashflows from investing activities - -4.82900M 0.00300M - 25.50M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.05M 0.26M 3.29M -1.82300M 13.50M
Sale purchase of stock 17.46M 3.59M 137.66M 2.54M 0.01M
Other cashflows from financing activities 0.23M 3.59M 27.20M 1.41M 0.01M
Change to netincome 17.84M 11.87M 4.36M 0.81M -4.16200M
Capital expenditures 9.60M 5.16M 1.22M 0.85M 0.71M
Change receivables 0.05M 0.26M 3.29M -1.82300M 13.50M
Cash flows other operating -9.58900M -5.20700M -2.51100M 0.72M 1.08M
Exchange rate changes - - - - -
Cash and cash equivalents changes -97.73200M 16.88M 113.34M 2.02M 9.94M
Change in working capital -4.69800M -2.12000M 2.81M 1.28M 2.45M
Stock based compensation 13.59M 8.87M 4.36M 0.63M 0.54M
Other non cash items -1.71500M -3.40700M -1.40300M -1.32100M -4.45300M
Free cash flow -104.38000M -64.98900M -24.97300M -13.94000M -15.25500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VXRT
Vaxart Inc		 0.02 3.32% 0.62 - 45.87 21.44 2.75 18.89 -1.9324
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Vaxart Inc

170 Harbor Way, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Cezar Andrei Floroiu M.B.A. CEO, Pres & Director 1973
Dr. Sean N. Tucker Sr. VP & Chief Scientific Officer 1968
Dr. James F. Cummings M.D. Chief Medical Officer 1966
Mr. Fuad Ahmad Interim CFO and Principal Financial & Accounting Officer 1970
Dr. Raymond D. Stapleton Jr., Ph.D. Chief Technology Officer 1971
Mr. Edward B. Berg Sr. VP & Gen. Counsel 1964
Ms. Shaily Jaini Garg Sr. VP of Clinical Devel. & Project Management NA
Mr. Brant Biehn Sr. VP of Bus. Operations NA
Dr. Rajesh Kapoor Ph.D. Sr. VP of Quality NA
Mr. John M. Harland M.B.A., CPA Consultant 1952

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.